Onconova reports PhIII flop, putting high-risk MDS program on the chopping block
Beleaguered biotech Onconova ran into another setback Monday morning as a Phase III for its lead program flopped once again.
The trial results for rigosertib, which blocks cellular signaling by targeting RAS effector pathways, in high-risk myelodysplastic syndrome patients did not meet its primary endpoint of improved survival. In individuals who had tried and failed treatment with a hypomethylating agent, rigosertib plus best supportive care achieved overall survival of 6.4 months, compared to 6.3 months for patients on physician’s choice.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.